Happy & Healthy with Amy

Understanding ARIA: How Risky Are Leqembi and Kisunla?

• Amy Lang

Share episode

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 31:57

If your mom or dad has been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s, you may be weighing whether one of the newer treatments—Leqembi or Kisunla—could be worth considering.

And then you hear the words brain swelling and bleeding.

For a lot of families, that’s the moment the conversation stops.

But here’s the problem: those words don’t tell you the whole story.

The ARIA rates reported in Alzheimer’s drug trials can sound alarming when you hear them on their own. What they don’t tell you is what those cases actually looked like, how often symptoms occurred, why some people are at higher risk than others, or how doctors monitor for problems before they become more serious.

That’s what we’re unpacking in Part 2 of this three-part series.

In this episode, I’ll walk you through what ARIA—amyloid-related imaging abnormalities—actually means, why it happens, how it differs from an infusion reaction, and why the top-line percentages may not tell you nearly enough about your loved one’s individual risk.

We’ll also look at an important question that doesn’t get enough attention:

Why can two people taking the same Alzheimer’s drug have very different risk profiles?

And there’s one more piece of the story that matters if you’re comparing Leqembi and Kisunla. The numbers from the original clinical trials are not necessarily the whole picture today.

WHAT TO LISTEN FOR

  • [00:00] Why hearing “brain swelling and bleeding” can make these treatments sound scarier than the full data suggests
  • [05:05] How to tell the difference between an infusion reaction and something happening specifically in the brain
  • [10:18] What the ARIA spectrum actually looks like—and why one percentage can hide very different outcomes
  • [14:17] Why comparing the headline ARIA rates for Leqembi and Kisunla may lead you to the wrong conclusion
  • [16:48] The blood-vessel condition that may help explain why ARIA happens in the first place
  • [20:53] Why APOE4 status can dramatically change the risk conversation
  • [20:53] What a baseline MRI can reveal before treatment even begins
  • [20:53] Why blood thinners make the risk-benefit discussion more complicated
  • [20:53] How ARIA can mimic a stroke—and why that matters in an emergency
  • [25:57] Why anti-amyloid drugs are only one piece of a much bigger Alzheimer’s treatment strategy

BEFORE YOU DECIDE THE RISK IS TOO HIGH

The big takeaway from this episode is that a clinical-trial ARIA percentage is not the same thing as your loved one’s individual risk.

  • The type of ARIA matters.
  • Whether symptoms are present matters.
  • Genetics matter.
  • Baseline MRI findings matter.
  • Other medications matter.
  • And even the way the drug is dosed may matter.

That’s why this decision deserves more than a scary headline or a single percentage.

In Part 1, we looked at the potential benefits of these newer anti-amyloid treatments. In this episode, we’re looking at the risks. And in Part 3, we’ll put both sides together and walk through a framework you can use to have a more informed conversation with your neurologist.

If this episode helps you better understand the questions worth asking, follow or subscribe to Happy and Healthy with Amy so you don’t miss Part 3.

And please share this episode with someone who is trying to make sense of an Alzheimer’s diagnosis or treatment decision.

Because the more you understand what the numbers actually mean, the better prepared you’ll be to ask the questions that matter.

This episode is for educational purposes only and is not medical advice. Please work with a licensed healthcare professional for diagnosis and treatment decisions.

RESOURCES: